Bivalirudin in STEMI

Bivalirudin is a direct thrombin inhibitor, and in the HORIZONS-AMI trial was compared with heparin and a glycoprotein inhibitor in patients undergoing primary percutaneous coronary intervention, where it was shown to be associated with lower rates of bleeding and thrombocytopaenia, with similar rates of survival at 30 days. The one-year follow up results are now published, confirming reduced rates of major bleeding and mortality.
Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial
Lancet. 2009 Oct 3;374(9696):1149-59

Leave a Reply

Your email address will not be published. Required fields are marked *